{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:24:48Z","timestamp":1779315888769,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:00:00Z","timestamp":1539993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10067-018-4339-0","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T03:54:36Z","timestamp":1540007676000},"page":"749-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["IgG levels in Kawasaki disease and its association with clinical outcomes"],"prefix":"10.1007","volume":"38","author":[{"given":"Marco Antonio","family":"Yamazaki-Nakashimada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa Berenise","family":"G\u00e1mez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumi","family":"Yasukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,20]]},"reference":[{"issue":"8232","key":"4339_CR1","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Sch\u00f6ni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrmobocytopenic purpura in childhood. Lancet 1(8232):1228\u20131231","journal-title":"Lancet"},{"issue":"8411","key":"4339_CR2","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0140-6736(84)91504-6","volume":"2","author":"K Furusho","year":"1984","unstructured":"Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T et al (1984) High dose intravenous gammaglobulin for Kawasaki disease. Lancet 2(8411):1055\u20131058","journal-title":"Lancet"},{"issue":"8617","key":"4339_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(88)92650-5","volume":"2","author":"S Nishihara","year":"1988","unstructured":"Nishihara S, Ishibashi K, Iribe K, Matsuda I (1988) Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet 2(8617):973","journal-title":"Lancet"},{"key":"4339_CR4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0022-3476(97)70038-6","volume":"131","author":"M Terai","year":"1997","unstructured":"Terai M, Shulman ST (1997) Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gammaglobulin dose but independent of salicylate dose. J Pediatr 131:888\u2013893","journal-title":"J Pediatr"},{"issue":"6","key":"4339_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJM198608073150601","volume":"315","author":"JW Newburger","year":"1986","unstructured":"Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315(6):341\u2013347","journal-title":"N Engl J Med"},{"issue":"23","key":"4339_CR6","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","volume":"324","author":"JW Newburger","year":"1991","unstructured":"Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner HC, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324(23):1633\u20131639","journal-title":"N Engl J Med"},{"key":"4339_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1442-200X.1998.tb01915.x","volume":"40","author":"T Sawaji","year":"1998","unstructured":"Sawaji T, Haneda N, Yamaguchi S, Kajino Y, Kishida K, Seto S, Konishi N et al (1998) Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications. Acta Paed Japonica 40:218\u2013225","journal-title":"Acta Paed Japonica"},{"key":"4339_CR8","unstructured":"Stiehm ER, Ochs H, Winkelstein J (2004) Immunodeficiency disorders. General considerations, in Stiehm, Ochs, Winkelstein, Elsevier Saunders, fifth edition, Philadelphia, pag 307"},{"issue":"1","key":"4339_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, Wilkes MM (2010) Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 137(1):21\u201330. https:\/\/doi.org\/10.1016\/j.clim.2010.06.012","journal-title":"Clin Immunol"},{"issue":"7","key":"4339_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1586\/1744666X.2015.1044980","volume":"11","author":"JC Burns","year":"2015","unstructured":"Burns JC, Franco A (2015) The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol 11(7):819\u2013825. https:\/\/doi.org\/10.1586\/1744666X.2015.1044980","journal-title":"Expert Rev Clin Immunol"},{"key":"4339_CR11","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/adc.2010.184101","volume":"96","author":"JY Hwang","year":"2011","unstructured":"Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, Lee JS, Burgner D (2011) Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Arch Dis Child 96:1088\u20131090","journal-title":"Arch Dis Child"},{"issue":"5","key":"4339_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3345\/kjp.2018.61.5.160","volume":"61","author":"YM Seo","year":"2018","unstructured":"Seo YM, Kang HM, Lee SC, Yu JW, Kil HR, Rhim JW, Han JW, Lee KY (2018) Clinical implications in laboratory parameter values in acute Kawasaki disease for early diagnosis and proper treatment. Korean J Pediatr 61(5):160\u2013166","journal-title":"Korean J Pediatr"},{"issue":"2","key":"4339_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000363383","volume":"164","author":"K Yanagimoto","year":"2014","unstructured":"Yanagimoto K, Nomura Y, Masuda K, Hirabayashi M, Morita Y, Yoshishige M, Ueno K, Eguchi T, Kawano Y (2014) Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease. Int Arch Allergy Immunol 164(2):83\u201388. Error! Hyperlink reference not valid. https:\/\/doi.org\/10.1159\/000363383.","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"4339_CR14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1542\/peds.96.6.1057","volume":"96","author":"K Durongpisitkul","year":"1995","unstructured":"Durongpisitkul K, Gururaj VJ, Park JM, Martin CF (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96(6):1057\u20131061","journal-title":"Pediatrics"},{"key":"4339_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/chd.12502","volume":"12","author":"JW Newburger","year":"2017","unstructured":"Newburger JW (2017) Kawasaki disease: medical therapies. Congenit Heart Dis 12:641\u2013642. Error! Hyperlink reference not valid. https:\/\/doi.org\/10.1111\/chd.12502.","journal-title":"Congenit Heart Dis"},{"issue":"5","key":"4339_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1046\/j.1442-200x.2000.01288.x","volume":"42","author":"Y Morikawa","year":"2000","unstructured":"Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, Katoh T, Baba K, Furusho K, Okuni M, Osano M (2000) Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatr Int 42(5):464\u2013469","journal-title":"Pediatr Int"},{"issue":"4","key":"4339_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1442-200X.1994.tb03199.x","volume":"36","author":"Y Morikawa","year":"1994","unstructured":"Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, Katoh T, Baba K, Furusho K, Okuni M et al (1994) A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatr Jpn 36(4):347\u2013354","journal-title":"Acta Paediatr Jpn"},{"issue":"29","key":"4339_CR18","doi-asserted-by":"publisher","first-page":"e7583","DOI":"10.1097\/MD.0000000000007583","volume":"96","author":"JW Han","year":"2017","unstructured":"Han JW, Oh J, Rhim JW, Lee KY (2017) Correlation between elevated platelet count and immunoglobulin levels in the early stage of KD. Medicine 96(29):e7583. https:\/\/doi.org\/10.1097\/MD.0000000000007583.","journal-title":"Medicine"},{"key":"4339_CR19","first-page":"26","volume":"47","author":"KY Lee","year":"2015","unstructured":"Lee KY (2015) A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis. Infect Chemother 47:26","journal-title":"Infect Chemother"},{"key":"4339_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.21737","volume":"66","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard K, de Gelder J, Tio-Guillen AP, Hop WCJ, van Gelder T et al (2009) Pharmacokinetics of intravenous immunoglobulins and outcome in Guillain Barre syndrome. Ann Neurol 66:597\u2013603. Error! Hyperlink reference not valid. https:\/\/doi.org\/10.1002\/ana.21737.","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"4339_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1529-8027.2011.00304.x","volume":"16","author":"PA Doorn van","year":"2011","unstructured":"van Doorn PA, Kuitwaard K, Jacobs BC (2011) Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP. J Peripher Nerv Syst 16(Suppl 1):38\u201340. Error! Hyperlink reference not valid. https:\/\/doi.org\/10.1111\/j.1529-8027.2011.00304.x.","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"4339_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1161\/01.CIR.0000079166.93475.5F","volume":"108","author":"M Terai","year":"2003","unstructured":"Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y (2003) Prognostic impact of vascular leakage in acute Kawasaki disease. Circulation 108(3):325\u2013330. https:\/\/doi.org\/10.1161\/01.CIR.0000079166.93475.5F","journal-title":"Circulation"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4339-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T09:36:22Z","timestamp":1662284182000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4339-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,20]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4339"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4339-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,20]]},"assertion":[{"value":"8 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Marco Yamazaki-Nakashimada declares having received lecture fees from Octapharma, CSL Behring and Shire; the other authors declare not having any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}